New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19

New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
A University of Minnesota assistant professor is part of a team that has developed a new way to effectively deliver vaccines through the nose that could lead to better protection against diseases like HIV and COVID-19. Credit: Hartwell Immunoengineering Lab, University of Minnesota

A University of Minnesota assistant professor is part of a team that has developed a new way to effectively deliver vaccines through mucosal tissues in the nose that could lead to better protection against pathogens like human immunodeficiency virus (HIV) and SARS-CoV-2, the virus that causes COVID-19.

The researchers tested the technology on mice and and found that the generated strong immune responses, paving the way for further study and development of nasal vaccines.

The study is published in Science Translational Medicine.

Historically, nasal vaccines—which would be administered through a nebulizer or spray—have been difficult to make successfully. The mucus in the typically clears out or breaks down the vaccine's components, such as , before they can access underlying tissues to activate the body's immune cells.

However, nasal vaccines have the potential to generate even more immunity than current vaccines administered by injection with needles. This is because for many diseases that are transmitted through the upper respiratory system, such as COVID-19, nasal vaccines have the potential to trigger immune responses in the exact areas of infection—the nose, mouth, and lungs. Some nasal vaccines do exist, but most use live attenuated pathogens, which cannot be given to people who are immunocompromised.

"Traditional vaccines that are injected are not usually geared toward establishing immunity in these mucosal tissues," explained Brittany Hartwell, first author on the paper and an assistant professor in the University of Minnesota Twin Cities Department of Biomedical Engineering. "They're more geared toward establishing immunity in the blood—sort of like a backup defense. But the idea of establishing immunity in the mucosal areas, like the nose, is that it establishes more of a frontline defense that can better protect against transmission of these diseases."

Hartwell said that with this new vaccine, not only did they establish strong mucosal antibody responses, but they also activated really strong antibody responses in the blood.

"So, it's kind of like we're establishing a frontline and backup defense at the same time," she said.

Hartwell and her team have found a way to help vaccine antigens bypass the mucosal barriers in the nose by engineering them to bind onto a protein called albumin, which naturally occurs in the and has the ability to get around these roadblocks. The antigens could then effectively "hitchhike" on albumin to get to their destination—the immune tissues underlying in the nose—to start activating an immune response.

And, the researchers' vaccine proved effective at generating immunity not just in the nose, but in other mucosal tissues of the body as well, which include the upper respiratory system, lungs, and genitourinary tract. The latter is especially relevant for vaccinating against a virus like HIV, which is transmitted through those sites.

"This is really significant for the field of mucosal vaccination," Hartwell said. "It shows something new, that we've designed a vaccine capable of overcoming barriers to delivery that have historically plagued the development of other mucosal vaccines. It's particularly relevant right now because we're all living in the midst of the COVID pandemic that's continuing to affect our lives. And as long as there's spread and transmission, the virus has a chance to evolve into new variants with the potential to be harmful. This research shows the development of a slightly different kind of vaccine that could provide even better protection than what we currently have by blocking transmission, preventing us from catching and passing the virus onto others."

Hartwell is continuing to study and develop this new vaccine technology in her lab at the University of Minnesota Twin Cities and hopes to adapt it to other diseases and illnesses in the future.


Explore further

New needle-free nasal vaccine shows promise for COVID-19

More information: Brittany L. Hartwell et al, Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity, Science Translational Medicine (2022). DOI: 10.1126/scitranslmed.abn1413
Journal information: Science Translational Medicine

Citation: New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19 (2022, August 10) retrieved 1 October 2022 from https://medicalxpress.com/news/2022-08-method-nasal-vaccine-delivery-vaccines.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
66 shares

Feedback to editors